PTSD remission after prolonged exposure treatment is associated with anterior cingulate cortex thinning and volume reduction by Helpman, Liat et al.
DEPRESSION AND ANXIETY 33:384–391 (2016)
Research Article
PTSD REMISSION AFTER PROLONGED EXPOSURE
TREATMENT IS ASSOCIATED WITH ANTERIOR
CINGULATE CORTEX THINNING AND VOLUME
REDUCTION
Liat Helpman, Ph.D., Santiago Papini, M.A., Binod T. Chhetry, M.S., Erel Shvil, Ph.D., Mikael Rubin, M.A.,
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Background: Brain structures underlying posttraumatic stress disorder (PTSD)
have been a focus of imaging studies, but associations between treatment outcome
and alterations in brain structures remain largely unexamined. We longitudi-
nally examined the relation of structural changes in the rostral anterior cingulate
cortex (rACC), a previously identified key region in the PTSD fear network, to
outcome of prolonged exposure (PE) treatment. Method: The sample included
78 adults (53 women): 41 patients with PTSD and 37 trauma-exposed healthy
volunteers (TE-HCs). Patients underwent a 10-week course of PE treatment and
completed pre- and posttreatment assessments and magnetic resonance imaging
(MRI) structural scans. TE-HCs also underwent assessment and MRI at base-
line and 10 weeks later. PE remitters (n = 11), nonremitters (n = 14), and
TE-HCs, were compared at baseline on demographic and clinical characteristics
and ACC structure. Remitters, nonremitters, and TE-HCs were compared for
pre- to posttreatment clinical and structural ACC change, controlling for po-
tential confounding variables. Results: There were no baseline differences in
structure between PTSD and TE-HCs or remitters and nonremitters. Following
treatment, PTSD remitters exhibited cortical thinning and volume decrease in
the left rACC compared with PTSD nonremitters and TE-HCs. Conclusions:
These results, while in need of replication, suggest that PE treatment for PTSD,
by extinguishing maladaptive trauma associations, may promote synaptic plas-
ticity and structure change in rACC. Future research should explore possible
underlying mechanisms. Depression and Anxiety 33:384–391, 2016. C© 2016
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Posttraumatic stress disorder (PTSD) is a debilitating
disorder with widespread effects on physical health,[1]
functioning,[2] and interpersonal relationships.[3] Among
evidence-based treatments for PTSD,[4, 5] prolonged ex-
posure (PE) is considered the gold standard.[6] To re-
duce the excessive fear associated with trauma mem-
ories and reminders through habituation and eventual
extinction,[7] PE patients repeatedly recount trauma
memories and challenge trauma-related avoidances in
graded fashion. Although PE shows moderate-to-high
efficacy,[8] individual differences in response and remis-
sion are not fully understood, and neurobiological treat-
ment mechanisms such as changes in the neural circuits
implicated in fear processing remain unexplored.
Research on neural underpinnings of PTSD has previ-
ously described the role of the amygdala, hippocampus,
and prefrontal cortex (PFC).[9] Yet, emerging evidence
more specifically implicates the anterior cingulate cortex
(ACC) as a key prefrontal region in posttraumatic symp-
toms and treatment response. Although ACC influences
executive control of emotional responses,[10] its role in
PTSD is not fully understood. Previous structural stud-
ies have found either no differences between patients
and controls in ACC cortical thickness and volume[11, 12]
or a negative relationship between symptom severity, or
diagnostic status, and thickness or volume of ACC.[13–16]
Methodological differences may explain these contradic-
tory findings: use of volume only in some studies,[16] both
volume and cortical thickness in others,[11, 12] and exami-
nation of different ACC regions (e.g., separate examina-
tion of caudal and rostral aspects vs.[14] examining entire
ACC,[12, 16]) and use of varied, homogeneous samples
(veterans only,[11, 14] female victims of sexual abuse,[12]
victims of urban violence[13]). However, a recent meta-
analysis associates a smaller ACC with PTSD.[15] More-
over, this region predicts treatment response in PTSD.
Larger left rostral ACC volume pretreatment,[17] as well
as greater left rACC gray matter density, predicted better
treatment outcome in cognitive behavioral therapy.[18]
The left rACC was linked to emotional appraisal[19]
and to resolving emotional conflict by inhibiting
amygdala.[20] This is consistent with left lateralization
of positive affect and approach motives.[21] If exposure
therapy theoretically engages fear circuits and results
in habituation, extinguishing maladaptive connections
between innocuous but trauma-associated stimuli and
fear circuitry, changes in this brain region may follow.
Findings of thicker and denser pretreatment ACC in
CBT responders[18] could indicate excess connectivity,
representing the maladaptive connections requiring
extinction in PE, perhaps due to futile attempts to
inhibit amygdala in the face of continued activation,
and might mark the best candidates for PE. This would
lead us to hypothesize decreased thickness and volume
following PE. The findings of thinner, or smaller, ACC
in PTSD[15] may suggest an alternative mechanism
wherein ACC is hypoactive, possibly due to avoidance;
failing to inhibit amygdala; and having smaller volume
due to diminished connectivity. A thicker, larger ACC
might then be expected at the end of treatment. Sup-
porting this hypothesis is the finding associating better
response to exposure-based therapy for OCD with a
thinner pretreatment left rACC.[22]
Only one published study has assessed posttreatment
ACC structural changes, reporting null findings.[17]
This study, however, examined pharmacotherapy, not
exposure-based psychotherapy treatment, and examined
changes only in the right subgenual ACC, which partly
overlaps with ventral right rACC. It did not describe left
ACC, and did not therefore gauge structural changes
in left rACC previously associated with treatment
outcomes.
Evidence associates ACC structure with PTSD symp-
toms and treatment, generally associating ACC reduc-
tion/thinning with PTSD. Thicker/larger left rACC,[18]
as detailed above, may predict favorable treatment out-
comes. However, structural changes associated with
treatment have received little exploration, and the mech-
anism behind existing findings remains unclear. The cur-
rent study therefore examined the association between
changes in rACC thickness and volume and treatment re-
mission, comparing patients with PTSD who remitted
following treatment to nonremitters. Trauma-exposed
healthy controls (TE-HCs) without PTSD, matched for
age, ethnicity, and trauma, provided another compari-
son to allow examination of baseline differences and to
control for nontreatment-related changes in left rACC
structure followed over an identical interval. We ex-
pected the rACC to associate with treatment outcome,
generating three a priori hypotheses:
H1: Pretreatment left rACC volume and thickness will
be greater in the TEHC than in the PTSD group.
H2: Greater pretreatment left, but not right, rACC
thickness and volume will be associated with re-
mission after treatment in the PTSD group.
H3: At posttreatment follow up, remission status will
be associated with left rACC thickness and volume
changes. Specific direction is not hypothesized.
MATERIALS AND METHODS
SAMPLE AND PROCEDURE
PTSD patients and matched TE-HC subjects were recruited via
advertisement and fliers. All participants met DSM-IV PTSD crite-
rion A1 for adult traumatic events, including vehicular accidents, sexual
or physical assaults, and witnessing serious injuries or deaths. Medi-
cal history, review of systems, physical examination, and laboratory
tests determined participant health status. Two trained raters admin-
istered the Structured Clinical Interview for DSM-IV Axis I Disorders
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Figure 1. Enrollment flowchart. TEHC, trauma-exposed healthy controls; PTSD, posttraumatic stress disorder; ITT, intent to treat;
MR, magnetic resonance
(SCID),[23] Hamilton Depression Rating Scale (HAM-D-17),[24] and
the Clinician-Administered PTSD Scale (CAPS)[25] for DSM-IV to as-
sess PTSD diagnosis and clinical severity. Training was received from
a licensed senior clinician on conducting these prior to commencing
evaluations, and their interrater reliability score ranged between .92
and .99.
For PTSD subjects, exclusion criteria included substance/alcohol
dependence within the past 6 months or abuse within past 2 months,
use of any psychotropic medication 4 weeks prior to participation (6
weeks for fluoxetine), HAM-D-17 score >24, or CAPS score <50. Ex-
clusion criteria for TE-HC subjects were any current or past Axis I dis-
orders, and CAPS scores >19 (considered symptomatic).[25] The New
York State Psychiatric Institute Institutional Review Board approved
all procedures, and all participants provided written informed consent
for this clinicaltrials.gov-registered trial (identifier NCT01576510).
While 78 participants consented and were included in intent-to-treat
analyses, dropout, as well as data processing issues (e.g., movement
in the MRI), yielded a completer sample of 51 subjects, including 26
TE-HCs and 25 PTSD patients (see Fig. 1).
All PTSD patients entered treatment with one of two trained thera-
pists who adhered to the 10-week standard Foa et al. protocol.[8] Each
therapist treated a minimum of two pilot cases to ensure expertise.
Treatment sessions were audiotaped, monitored for adherence, and
supervised by PE experts to ensure adherence and competence using
the PE integrity measure developed by Foa et al.[26] Patients received
independent evaluations and MRI scans pretreatment and posttreat-
ment (week 10).
STRUCTURAL DATA
All T1-weighted structural images were acquired on a 1.5 T GE
Twin Speed MR Scanner operating on the Excite 3 12.0 M4 HD
platform with an eight-channel head coil. After inspection for motion
artifacts and gross abnormalities, mean cortical thickness and volume
values for anatomical regions were obtained by preprocessing the T1
images using Freesurfer 5.1.0 (http://surfer.nmr.mgh.harvard.edu)
standard surface-based reconstruction pipeline. A complete descrip-
tion of the pipeline can be found in other studies;[27,28] technical details
of the procedures are described in other studies.[27,29] No manual
intervention was required. Both intensity and continuity information
of the 3D T1 volume are used in Freesurfer’s segmentation and defor-
mation operations to produce estimate of cortical thickness, which is
calculated as the closest distance from the gray/white boundary to the
gray/CSF boundary at each vertex on the tessellated surface.[28] These
cortical thickness maps do not rely solely on absolute signal intensity, as
they are created using spatial intensity gradients across tissue classes. As
the cortical thickness maps produced are not restricted to the voxel res-
olution of the original data, they can identify submillimeter differences
Depression and Anxiety
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TABLE 1. Baseline symptom and structure differences between groups
TE-HC PTSD
Mean SD Mean SD F (df) P
TBV (mm3) 217441.591 18506.455 215157.608 23004.117 0.228 (1,76) .634
lrACC volume (mm3) 2559.189 463.566 2602.200 673.247 0.105 (1,76) .747
rrACC volume (mm3) 2134.622 469.849 2266.100 576.646 1.191 (1,76) .279
lrACC thickness (mm) 2.604 0.188 2.671 0.172 2.624 (1,76) .109
rrACC thickness (mm) 2.615 0.206 2.651 0.262 0.430 (1,76) .514
CAPS 4.438 5.962 80.6348 15.580 85.267 (1,72) <.001
HAM-D 2.219 2.420 16.512 5.577 82.857 (1,72) <.001
PTSD, posttraumatic stress disorder; TE-HC, trauma-exposed healthy controls; TBV, total brain volume; lrACC, left rostral anterior cingulate
cortex; rrACC, right rostral anterior cingulate cortex; CAPS, clinician assessment of posttraumatic symptoms; HAM-D, Hamilton Depression
Rating Scale
between groups. Procedures for measuring cortical thickness have been
validated against histological analysis and manual measurements.[30–32]
Freesurfer morphometric procedures show good test-retest reliability
across scanner manufacturers and across field strengths.[33]
ANALYTIC STRATEGY
PTSD patients and TE-HCs were compared for pretreatment dif-
ferences in lrACC, rrACC, and total brain volume (total brain volume
[TBV], included to rule out non-ROI specific trends), as well as de-
mographic differences (to gauge possible differences between remit-
ters and nonremitters warranting control in further analyses), using
ANOVA, to test H1. We expected thickness and volume to follow a
TE-HC > PTSD pattern. To test H2, we conducted two MANOVAs,
comparing baseline left rACC volume and thickness among remitters
and nonremitters within the completer sample, controlling for sex, age,
and TBV. We expected thickness and volume to follow a remitters >
nonremitters pattern.
To test H3, we first conducted two general linear mixed models
(GLMM) analyses on the intent-to-treat sample, maximizing power
and reducing type I error probability.[34] Maximum likelihood (ML)
method was used. lrACC thickness, then volume, were the dependent
variables. Time, TBV, and age were entered as covariates. Remission
status and sex were entered as between-subject factors. Time was de-
fined as a repeated measure including pre- and posttreatment lrACC
mean thickness or volume values, and remission status included effect
coding for nonremitters (0), remitters (1), and TE-HCs (-1). TE-HCs
were included in order to control the effects of time that are unrelated
to treatment. Remission from PTSD was defined a priori as CAPS
score posttreatment <20.[25] We examined main effects of time and
remission status and added interaction of time by remission status in or-
der to gauge effects for the relationship between structural changes and
symptom reduction (time × CAPS percent reduction). Due to sample
size, there would be insufficient power for analyses including additional
interactions, but the entry of sex as a variable in the model served to
control possible confounds related to sex differences.[35] Power analy-
ses were conducted using G-Power software and provided an estimate
of medium-to-high effect sizes (f = .32) required in order to reach
acceptable (.80) power.
We additionally conducted two repeated-measures ANOVAs, one
for mean volume and one for mean thickness, with a 2 × 3 design
(time × remission status), using only the completer subsample. This
aimed to further minimize probability of type II error.[34] Age, sex,
and TBV covariates statistically controlled the variance attributable
to these variables in these analyses. Power analyses were conducted
using G-Power software and provided an estimate of high effect sizes
(f = .45) required in order to reach acceptable (.80) power.
Several control analyses were conducted as follows: (1) Repeated
measures analyses were conducted adding depression symptoms and
years of education as covariates due to findings of between-group dif-
ferences in these variables (see results), as well as time since trauma
(chronicity) and age at first trauma (early exposure), due to purported
structural change. (2) All analyses testing between-group differences
were repeated using the remission variable created in accordance with
the HAM-D clinical cutoff,[24] to test specificity of results to PTSD
remission. (3) All analyses conducted with left ACC as the dependent
variable were repeated for right ACC to test specificity of findings for
this ROI. (4) Baseline analyses of differences between completers and
dropouts were conducted to exclude confounds due to dropout. None
of these analyses yielded significant results, supporting the specificity
and validity of the findings reported below.
RESULTS
No baseline differences were found between PTSD
patients and controls on any demographic variables ex-
cept years of education (see Table 2). No hypothesized
differences between groups in baseline rACC were ob-
served (see Table 1): thus data did not support H1.
Group differences were identified, as expected, in clinical
symptoms of depression (HAM-D) and PTSD (CAPS)
(Table 1). Similarly, results of the MANOVA did not
support H2, showing no differences among remitters,
nonremitters, and controls with regards to baseline left
rACC thickness and volume when controlling for TBV,
sex, and age (F [4,114] = 1.515, P = .203).
The results of the GLMM analysis supported H3,
finding a significant interaction effect for remission
status and time. A significant overall mean decrease
in lrACC volume (Estimate = 30.930, t = 2.194,
P = .033) and thickness (Estimate = −.019, t = −2.792,
P = .007) over time was seen across the three remission
status groups. Contrasts indicated lower lrACC mean
thickness (Estimate = −.155, t = −2.403, P = .019)
but comparable mean volume (Estimate = −15.333,
t = −.076, P = .940) over both time points for TE-HCs
when compared to remitters, and no differences in
mean lrACC thickness (Estimate = −.082, t = −1.091,
P = .279) or volume (Estimate = −29.107, t = −.125,
P = .901) over both time points when comparing non-
remitters to remitters. Contrasts for interaction effects
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TABLE 2. Baseline demographics and differences between groups
TE-HC PTSD
Mean SD Mean SD F (df) P
Age 34.595 10.708 35.895 9.442 0.286 (1,76) .594
Years of education 15.290 1.935 14.244 1.972 14.285 (1,76) <.001
TE-HC PTSD χ ² P
Ethnicity White 29.7.3% 26.8% 3.056 .548




Gender Female 67.3% 68.6% .005 .945
indicated a significantly less steep slope for lrACC thick-
ness over time for TE-HCs (Estimate = .016, t = 2.012,
P = .049) and for nonremitters (Estimate = .025,
t = 2.711, P = .009) when compared to remitters. For
volume, contrasts indicated a nonsignificantly steeper
slope for remitters versus TE-HCs (Estimate = 26.489,
t = 1.590, P = .118 for TE-HC vs. remitter contrast)
and a significantly steeper slope for remitters versus non
remitters (Estimate = 46.808, t = 2.489, P = .016 for
nonremitters vs. remitters contrast). These results indi-
cate overall thinning and volume reduction from pre- to
posttreatment among remitters compared to nonremit-
ters, specifically, despite similar overall thickness and
volume. The effect for this contrast is robust: ICC .291
for volume, and ICC .371 for thickness (given this effect
size, post hoc estimated power, even computed using a
conservative N of completers only, was .958 and.998 for
the two analyses, respectively), and likely drives the main
effect seen for time, as this effect loses statistical signif-
icance when the interaction term is removed from the
model.
The repeated measures analysis results also supported
H3, finding a main effect for time (F [1,45] = 4.650,
P = .036, η2partial = .094) driven by a significant inter-
action effect for time by remission (F [2,45] = 3.340,
P = .044, η2partial = .129). Specifically examining differ-
ences in thickness between T1 and T2 revealed signif-
icant left rACC thinning from pre- to posttreatment in
remitters (Fig. 2A). Volume analyses yielded a similar
pattern (F [1,45] = 3.49, P = .07, η2partial = .072for time,
F [2,45] = 3.46, P = .04, η2partial = .133for time by remis-
sion), with a nonsignificant trend toward reduced vol-
ume for remitters posttreatment (Fig. 2B). However, as
the effect size was slightly lower than the estimate, the
interaction effects for time and group failed to reach ac-
ceptable levels of power (the observed power was .603
for effect on thickness and .629 for effect on volume).
Control analyses yielded no significant time by remission
effect for right rACC (rrACC) volume (F[2,45] = .174,
P = .841, η2partial = .008) or thickness (F [2,45] = .546,
P = .583, η2partial = .024), supporting the specificity of
the association of left rACC cortical thinning and vol-
ume reduction with remission.
DISCUSSION
We found that remission from PTSD following pro-
longed exposure treatment was associated with volume
reduction and thinning in the left rostral ACC (rACC).
Thickness and volume of left or right rACC did not
differ among the study groups before treatment, nor did
associations appear between baseline ACC structure and
baseline diagnostic status. While our findings are in line
with previous studies finding no such differences in cor-
tical thickness and volume among diverse groups such
as veterans and female victims of sexual assault,[11, 12]
other studies, also in diverse groups including veterans
and victims of violence, did uncover between-group
differences.[13–16] This inconsistency may be attributed
to methodological differences (e.g. sample and measure-
ment) and heterogeneity of PTSD.[36, 37] Our finding of
thinning and volume reduction in this brain region in
treatment remitters, but not nonremitters or controls,
in a diverse sample, links the structural changes to treat-
ment recovery specifically, rather than a general effect
of completing PE treatment, or passage of time. This is
the first evidence of neural structural change associated
with efficacy of a psychotherapy based on processing and
extinction of fear memories following PTSD-inducing
traumatic experiences. Contrasting our findings with
previous null findings regarding structural changes
in this region over the course of pharmacotherapy[17]
further emphasizes the possible role of this spe-
cific treatment mechanism in bringing about these
changes, as opposed to reflecting mere symptom
reduction.
These novel findings, showing structural change
during the course of PE, do not directly gauge the
mechanism of such change. However, previous litera-
ture provides a possible explanatory basis for how PE
treatment may effect therapeutic benefit. Exposure treat-
ment purportedly promotes extinction of maladaptive
cognitive–emotional connections.[7, 8] When translated
to neural connectivity, as constant activation of specific
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Figure 2. Changes in left rostral anterior cingulate cortex pre- to posttreatment. lrACC, left rostral anterior cingulate cortex.
pathways may reinforce existing connections and en-
courage the formation of new ones.[38] Extinction may
suppress this activation and prune those connections.
This process usually occurs into early adulthood,[39] but
adult animal models have also shown recovery from cor-
tical damage to occur later in life.[40–42] Therefore, thin-
ning in the left rACC, a region involved in the control of
emotional responses, may indicate changes in dendritic
morphology.
Stress-induced changes have been demonstrated in
prefrontal cortex synapse and dendritic spine morphol-
ogy and density, with differential effects in different ar-
eas, including ACC.[42] Treatment may partially reverse
such changes. Similar changes were previously shown to
follow sex-specific, estrogen-dependent patterns, with
stress-induced dendritic proliferation in females, and
an opposite effect in males.[42] Thus our observation of
ACC thinning following treatment remission may rep-
resent a pruning of overproliferated dendritic spines in
a mostly female sample. The robust effect for thickness,
but less so for volume, accords with this explanation, as
differences in sulcination and gyration add to variance in
cortical volume, but not thickness.[43, 44] Hence changes
in dendritic morphology would have greater impact on
thickness. Sex-related variance may also explain the lack
of baseline differences in PTSD symptoms between
PTSD and TE-HC subjects as, consistent with stress-
related proliferation, thinner baseline ACC thickness
may be associated with PTSD symptoms for men
but not women.[12] That pruning drives the efficacious
treatment-related thinning would not only be congruent
with PE theory—reducing dendritic spines while habit-
uating to traumatic associations—but with the positive
relationship previously found between pretreatment
rACC thickness and gray matter density and PTSD
treatment outcome,[18] as patients with greater baseline
rACC connectivity may benefit most from exposure-
based treatment. However, our sample showed no such
difference in rACC thickness prior to treatment.
It is also important to note that findings may be seen
in a larger context of fear circuitry abnormalities in
PTSD. While this study particularly focused on the left
rACC, structural abnormalities in additional parts of this
circuitry, including hippocampus and amygdala, have
also been implicated in PTSD.[9] Specifically, previous
studies have showed hippocampal volume changes over
the course of pharmacotherapeutical treatment,[45, 46]
but treatment-stable hippocampal differences between
chronic and successfully treated PTSD patients have
also been found.[47] Although amygdala has not shown
treatment-related malleability,[46] it has evinced a spe-
cific pattern of connectivity to ACC among those with
PTSD.[48] Our data, consistently with several previous
studies, did not show change in these regions following
treatment (all P >.05); however, future studies examin-
ing network connectivity would be advised to examine
the interplay of these different regions.
Our findings, while significant, have limitations. Our
sample included mostly women and lacked statistical
power to test gender differences. Our repeated measures
analyses could not include treatment dropouts (N = 14)
who did not return for MRI follow-up assessments,
and our GLMM analysis only statistically controlled for
missingness; thus limitations inherent in a completer
sample, or a sample with missing data, apply: despite lack
of differences in baseline variables between completers
and dropouts, the study cannot describe trajectories of
structural changes among dropouts. Also, while evincing
desirable effect size and power within the ITT analyses,
these results require replication in larger samples in or-
der to ascertain generalizability, especially in light of the
post hoc loss of power in completer-only analyses due to
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a lower effect size than expected. Finally, our interpreta-
tion of the mechanism behind left rACC thinning (i.e.,
pruning of maladaptive connectivity to amygdala) needs
further testing using techniques gauging connectivity
and dendritic arborization. Future studies should enroll
larger, gender-balanced samples in order to further ex-
plore differences in structural correlates of treatment re-
sponse. Functional analyses, exploring possible changes
in connectivity pre- to posttreatment, may further elu-
cidate the mechanisms driving symptom change. Nev-
ertheless, our findings support the notion that exposure
treatment may, indeed, effect relatively rapid changes
in fear neurocircuitry, leading to clinical remission of
PTSD.
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